Clover Health: Garipalli Vivek Buys 415,000 Shares at $2.24/Share on 8/7/2025.

Clover Health Investments Corp. /DE [CLOV] has recently announced that Director and 10% Owner, Garipalli Vivek, has made two separate transactions. Firstly, on 2025-08-07, Vivek purchased 415,000 shares at a price of $2.24 per share. Secondly, on 2025-08-08, he acquired an additional 31,980 shares at a price of $2.17 per share.

Clover Health Investments Corp. /DE [CLOV], a healthcare technology company specializing in Medicare Advantage plans, has recently reported that Director and 10% Owner, Vivek Garipalli, has made two separate transactions in the company's Class A common stock. The transactions were reported to the U.S. Securities and Exchange Commission (SEC) on August 7, 2025, and August 8, 2025, respectively.

On August 7, 2025, Garipalli purchased 415,000 shares at a weighted average price of $2.24 per share. The following day, on August 8, 2025, he acquired an additional 31,980 shares at a weighted average price of $2.17 per share. These transactions increased Garipalli's direct ownership to 1,856,247 Class A shares.

The SEC filing also disclosed significant Class B common stock holdings that convert one-for-one into Class A shares. Garipalli's direct holdings include 6,904,343 Class A-equivalent shares, while his indirect holdings via Caesar Clover, LLC and NJ Healthcare Investments, LLC amount to 11,500,000 and 72,084,543 Class A-equivalent shares, respectively. Garipalli serves as the sole manager of these LLCs.

The reported purchases are notable for their alignment with the company's recent financial performance. Despite a net loss of $10.6 million in the second quarter of 2025, compared to a net income of $7.2 million in the same period last year, Clover Health has shown significant growth in total revenues, reaching $477.6 million from $356.3 million in the previous year. The company's membership grew to 106,323 members by June 30, 2025, from 80,261 members in the prior year.

Investors should note that while the insider buying is a positive signal, the governance implications remain given the concentrated Class B holdings held through managed LLCs. The filing is informative about the ownership structure but does not disclose any change in governance arrangements or conversion actions.

References:
[1] https://www.tradingview.com/news/tradingview:518465ae71b62:0-clover-health-investments-corp-de-sec-10-q-report/
[2] https://www.stocktitan.net/sec-filings/CLOV/form-4-clover-health-investments-corp-insider-trading-activity-7b382ee0e4a1.html